The U.S. Department of Justice has reached two settlements with pharmaceutical companies that will call for a total of more than $100 million in penalties under the False Claims Act and the Food, Drug and Cosmetic Act. The announcements came two days after the department reached the $520 million settlement with AstraZeneca.
In one of the settlements, two Johnson & Johnson subsidiaries, Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., will pay more than $81 million for the off-label promotion of the epilepsy drug Topamax. The FDA approved the drug for the treatment of partial onset seizures. However, the manufacturers also promoted the drug for psychiatric uses. Ortho-McNeil-Janssen Pharmaceutical’s promotion of the drug caused false claims to be submitted to government health care programs. The company will pay more than $75 million to settle civil allegations under the False Claims Act. It will also enter into a corporate integrity agreement with the Department of Health and Human Services to ensure the alleged violations aren’t repeated.
Ortho-McNeil Pharmaceutical will pay more than $6 million in criminal fines for violating the Food, Drug and Cosmetic Act. The company allegedly marketed the sale of Topamax by hiring outside physicians to join sales representatives on sales calls and speak at events promoting the drug for off-label uses.
In the other settlement, Schwarz Pharma Inc., a subsidiary of Belgium-based UCB S.A., will pay $22 million for violations of the False Claims Act regarding the drugs Deponit and Hyoscyamine Sulfate Extended Release. The company failed to tell the Centers for Medicare and Medicaid Services that the two products, neither of which were approved by the FDA, did not qualify for coverage under federal health care programs. Deponit is a skin patch used to prevent angina. Hyoscyamine Sulfate Extended Release treats various stomach, intestinal and urinary tract disorders. Neither product is now on the market. Both of these cases began as whistleblower lawsuits, which were filed under the False Claims Act.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.